You can buy or sell Mylan and other stocks, options, ETFs, and crypto commission-free!
Mylan N.V. Ordinary Shares, also called Mylan, is a pharmaceutical healthcare company. Read More The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
52 Week High
52 Week Low
Seeking AlphaMay 17
Assessing What Happens If Fitch Sacks Mylan
Mylan corporate logo. Source: Bloomberg Mylan's (NASDAQ:MYL) revenue and operating income are in rapid decline. Its $14 billion debt load makes the decline even more problematic. Fitch Ratings recently revised Mylan's outlook to negative and implied a downgrade could leave the company's debt with a junk rating: Fitch Ratings has affirmed Mylan's long-term Issuer Default Rating ("IDR") at 'BBB-' and its short-term IDR at 'F3'. The Rating Outlook is revised to Negative from Stable. The ratings apply to appr...
In win for Mylan, appeals court axes patents on arthritis drug Vimovo
A federal appeals court on Wednesday eased the way for Mylan NV and other generic drug companies to launch a generic version of Horizon Pharma PLC and Nuvo Pharmaceutical Inc’s arthritis drug Vimovo.
Yahoo FinanceMay 15
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
For Immediate Release Chicago, IL –May 15, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Teva Pharmaceutical Industries Ltd. TEVA, Mylan MYL, Novartis NVS and Pfizer PFE. Here are highlights from Tuesday’s Analyst Blog: Scroll to continue with content Ad Generic Drugmakers Face Antitrust Suit Alleging Price...
$0.80 per share
$0.82 per share